Nanovis Logo
Nanosurface Technology on Spinal Interbody
Nanotechnology Designation for Bioceramic Nanotube Surface

Nanovis Awarded Nanotechnology Designation for Bioceramic Nanotube Surface.

First Nanotechnology Designation for Bioceramic Nanotube Surface.

CARMEL, Indiana (Oct 22, 2019) – Nanovis today announced that it received the first 510(k) clearance for a bioceramic nanotube surface that demonstrated the FDA requirements for nanotechnology.

We are delighted to receive such an important designation for this new class of nanotechnology. This nanotechnology plays an important role in achieving Nanovis’ goal to reduce the pain and suffering from implant loosening. With this clearance we can rapidly apply this technology to our entire spinal implant portfolio so that we can help as many patients as possible and promote sales growth for the long-term.” says Nanovis CEO, Matt Hedrick.

Nanovis is an award-winning platform technology-driven growth company committed to helping surgeons and hospitals achieve excellent fixation and infection outcomes using advanced nanotechnology platforms. Its industry-leading fixation technologies offer surgeons and hospitals the best aspects of fixation, visualization, and durability. Nanovis’ developmental infection technology platforms promise to offer surgeons and hospitals much-needed bactericidal solutions.

Nanovis is actively expanding distribution for bioceramic nanotube enhanced Nano FortiCore interbodies.  To discuss opportunities, please contact Jeff Shepherd, Vice President of Sales, at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Nanovis

Nanovis discovers, develops, and commercializes innovative technology platforms designed for superior fixation and infection outcomes. Nanovis is commercializing the following innovative technology platforms: a bioceramic enhanced nanotube surface, a deeply porous titanium scaffold (licensed from Sites Medical), an advanced bioceramic bactericidal nanotube surface technology in pre-clinical studies, and a pre-clinical localized infection technology targeting anti-microbial resistant bacteria.


If you would like more information about Nanovis, please contact:              

Guillaume Viallaneix 

MedTech Momentum 

(407) 960-2994

This email address is being protected from spambots. You need JavaScript enabled to view it.

Connect With Us

Phone:  877.907.NANO

Recent News